Versor Investments LP Invests $634,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Versor Investments LP purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, Holdings Channel reports. The firm purchased 34,429 shares of the company’s stock, valued at approximately $634,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after acquiring an additional 1,173 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after acquiring an additional 1,212 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the sale, the insider now directly owns 159,796 shares of the company’s stock, valued at approximately $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares in the company, valued at $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Chi sold 7,500 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the sale, the insider now directly owns 193,980 shares in the company, valued at $4,306,356. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 854,547 shares of company stock valued at $15,987,230 in the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Up 3.4 %

Shares of HIMS stock opened at $27.60 on Thursday. The business’s fifty day moving average is $19.25 and its 200 day moving average is $18.70. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of 62.73 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $7.18 and a twelve month high of $30.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Truist Financial lifted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. TD Cowen increased their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Bank of America lifted their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.